---
title: "DualityBio drops 6% to record low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305622294.md"
description: "DualityBio fell 6.12% to HK$95.95. Down 7.92% over five sessions and down 67.82% YTD."
datetime: "2026-11-16T06:16:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305622294.md)
  - [en](https://longbridge.com/en/news/305622294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305622294.md)
generator: "portal-rs"
---

# DualityBio drops 6% to record low

DualityBio (9606.HK) fell more than **6%** in Hong Kong trading to a record low of **HK$95.95**.

The stock is down 7.92% over the past five sessions and down 67.82% year to date. It sits 74.54% below its 52-week high of HK$376.80. Volume was 0.48 times its average.

The Hang Seng Index is down 2.78% over the past five sessions and down 7.26% year to date.

The biotechnology industry index fell 3.6% over the same period.

An interim analysis of a Phase III trial for the company's core drug, patritumab deruxtecan, missed expectations. While the study met its primary endpoint of progression-free survival, the improvement was modest and the incidence of interstitial lung disease was elevated, limiting the clinical benefit.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [09606.HK](https://longbridge.com/en/quote/09606.HK.md)

## Related News & Research

- [Duality Biotherapeutics Chairman Zhu Plans to Double Share Purchases to Up to USD 10 Million](https://longbridge.com/en/news/303394132.md)
- [DUALITYBIO-B  Spends Over HKD17M on Buyback of 158,000 Shares on Wed](https://longbridge.com/en/news/303482424.md)
- [Tesla Cybercab’s ‘Autonomy Subscription’ covers all bases for a self-driving car](https://longbridge.com/en/news/306297563.md)
- [Tesla expands Supercharger Waitlist to 300 sites across the U.S.](https://longbridge.com/en/news/306189672.md)
- [The Tesla Cybercab Is Now Available In Dallas](https://longbridge.com/en/news/306159915.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**